RxDoctor Payments Data

William Hewitt, MD

Neurology · Mobile, ALNPI 1184668501

Payments from drug & device makers

$6,358in general payments, 2019–2025

Across 399 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$716
  • Teva Pharmaceuticals USA, Inc.$608
  • UCB, Inc.$397
  • Biogen$374
  • Amgen$286
  • plus $2K from 35 others

What the payments were for

  • Speaking & faculty fees$2003%
  • Food & beverage$6,15697%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,358 in reported general payments places this provider in the 55th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$37,857
Medicare patients
174
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate11$52,386
XcopriCenobamate19$29,203
AptiomEslicarbazepine Acetate11$25,779
BriviactBrivaracetam13$21,665
Dimethyl Fumarate15$20,146
QuliptaAtogepant11$14,926
Aimovig AutoinjectorErenumab-Aooe11$11,139
Lacosamide31$6,855
Levetiracetam83$3,100
Carbidopa-LevodopaCarbidopa/Levodopa43$2,643
Propranolol Hcl ErPropranolol Hcl20$1,902
Oxcarbazepine24$1,585
Gabapentin83$1,292
Memantine Hcl57$1,168
Donepezil Hcl139$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$71$52,38611 claims
SK Life Science, Inc.Xcopri$64$29,20319 claims
Sunovion Pharmaceuticals Inc.Aptiom$16$25,77911 claims
UCB, Inc.Briviact$397$21,66513 claims
AbbVieQulipta$2,142$14,92611 claims
Upsher-smith Laboratories LLCTopiramate$14$89465 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$58$86215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 neurology providers in Alabama.

Other neurology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →